For example, inavolisib (GDC-0077), a selective PI3Kα inhibitor, exhibits stronger cytotoxicity in PIK3CA-mutated breast cancer and demonstrates good antitumor effects in animal models (9). This evidence concerns the gene PIK3CA and breast carcinoma.